Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briquilimab, an antibody targeting KIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izeltabart, an antibody targeting ADAM9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamvatamig, an antibody targeting MET × EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bezetabart, an antibody targeting CD74.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teneliximab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sonavibart, an antibody targeting Influenza A HA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Danvilostomig, an antibody targeting CTLA-4 × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lintuzumab, an antibody targeting SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erlizumab, an antibody targeting ITGB2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Metelimumab, an antibody targeting TGF-beta1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Matuzumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fontolizumab, an antibody targeting IFNG.